In a matter involving an antitrust counterclaim, a generic pharmaceutical manufacturer alleged that a blockbuster brand manufacturer attempted to monopolize the market and delay entry of the generic product. A CRA expert was retained to analyze market definition, competitive effects, and lost profits damages estimates. The matter settled favorably for our client shortly before trial.
Physician Groups - The Next Enforcement Frontier for Healthcare Provider Mergers?
The Federal Trade Commission’s (FTC’s) recent announcement that it will be undertaking a retrospective study of physician group consolidations may signal an...